FDA Expands Dolutegravir Approval to Infants With HIV-1 Weighing at Least 2 kg

The FDA has expanded the approval of the HIV drug Dolutegravir to include infants with HIV-1 who weigh at least 2 kg, allowing earlier access to this treatment for a vulnerable patient group.

This Wire brief sits within Fusion42's coverage of Biotech.